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Abstract
Adherence to medication is one of the most significant challenges of secondary prevention in 
patients after an acute myocardial infarction (AMI). Indeed, it has been well established that 
higher adherence is associated with better cardiovascular outcomes. Research pertaining to 
secondary prevention after AMI treated with percutaneous coronary intervention (PCI) focuses 
mainly on the adherence to antiplatelet therapy. Adherence levels have been found to be particu-
larly poor and thus, insufficient with regards to prevention; with a high rate of discontinuation 
of therapy occurring during the 12-month follow-up. There are numerous predicting factors 
associated with non-adherence to antiplatelet therapy in patients after PCI. These include, but 
are not limited to, a lack of education on antiplatelet treatment, various comorbidities, depres-
sion, or even, unmarried status. Financial limitations of the patient also play a relevant role, 
however, the nature of this impediment is problematic and requires further investigation. It 
would seem beneficial to carry out advanced research based on a randomized and double-blind 
protocol, however, large-cohort, real-world observations are also essential to investigate non-
adherence across a broad array of treatment settings above and beyond the scope of prospective 
clinical trials. Research about adherence under the context of invasive treatment of AMI has  
a tremendous practical impact and should be considered a matter of importance concerning 
both clinicians and scientists. Close collaboration between not only researchers, health practi-
tioners, i.e. physicians and pharmacists, but also politicians, is strongly recommended to aid in 
designing an intervention that might improve patient adherence. (Cardiol J 2016; 23, 5: 483–490)
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coronary syndrome, percutaneous coronary intervention, platelet aggregation 
inhibitors
Introduction
Adherence to a medication regimen in post-
myocardial infarction patients is one of the most 
significant challenges of secondary prevention in 
cardiovascular medicine [1, 2]. Due to the high 
prevalence of comorbidities, and the multifactorial 
nature of cardiovascular diseases, the majority of 
patients often require combination therapy [3]. 
A complex drug regimen may prove to have 
a detrimental effect on patient adherence and con-
sequently, play a direct role in poorer therapeutic 
483www.cardiologyjournal.org
CLINICAL CARDIOLOGY
Cardiology Journal 
2016, Vol. 23, No. 5, 483–490
DOI: 10.5603/CJ.a2016.0048
Copyright © 2016 Via Medica
ISSN 1897–5593REVIEW ARTICLE
prognoses [4]. Therefore, improvement of patient 
adherence should be considered a common goal, 
not only of healthcare practitioners such as physi-
cians and pharmacists, but also that of the politi-
cians who create both nationwide and international 
frameworks of healthcare policy [5]. Many different 
factors associated with dual antiplatelet therapy 
(DAPT) non-adherence have been investigated in 
various treatment settings under a broad array of 
prospective clinical trials. In certain randomized 
clinical trials (RCTs), high-risk populations such 
as elderly patients, have been essentially under-
scored, particularly in acute coronary syndrome 
(ACS) subsets; this is of capital importance in 
regards to the interpretation of the diverse results 
obtained in differently designed studies. In the sci-
entific literature, there is a great deal of advanced 
research focused on adherence-related matters 
in regards to acute myocardial infarction (AMI), 
however, adherence in patients after AMI that have 
been treated with percutaneous coronary interven-
tion (PCI) still raises many unresolved questions. 
Patients after AMI with stent implantation are 
strongly recommended to implement antiplatelet 
therapy starting with a dual regime, namely DAPT 
which comprises of acetylsalicylic acid (ASA) and 
adenosine diphosphate receptor inhibitors e.g. 
clopidogrel, ticagrelor [6]. The strong correlation 
between the use of DAPT and the decrease in the 
rate of mortality after AMI is one of the most ac-
curate and well-documented cause-and-effect re-
lationships in this area of research. As antiplatelet 
agents are generally widely available, and in many 
cases, reimbursed by public resources or private 
insurance policies, it is entirely possible to receive 
high-quality data from pharmacy refill statistics.
Questions concerning adherence-related is-
sues after invasive treatment of AMI are not only 
a purely scientific matter, but also bear crucial 
practical consequences. Defining the important 
predictors of non-adherence remains a challenge 
both for clinicians and scientists. 
The aim of this paper is to present the current 
level of knowledge regarding adherence-related 
issues in the context of AMI treated with PCI. 
Additionally, we would like to add our voice to the 
discussion on the practical aspects and implications 
of research conducted on adherence-related issues.
Treatment adherence: Methodological  
issues and definition
Experts, who focus mainly on adherence in 
their works, state that in their opinion, the current 
literature available describing adherence-related 
behaviors is only in the initial stages. They be-
lieve this is just the beginning of methodological 
development [7]. While there are several well-
established methods to assess adherence, none of 
them fulfill high-quality scientific and clinical re-
quirements [8]. Moreover, methodological impedi-
ments have emerged; for instance, self-reported 
questionnaires — the cheapest and the easiest way 
to measure the adherence level, have over- or un-
der-estimated this phenomenon [9, 10]. It should 
be noted that medical records, patient databases 
and pharmacy refill statistics, all which clearly aid 
in evaluating adherence in a large patient cohort; 
oversimplify the multidimensional character of 
adherence [11]. The use of a pill count tracker 
or electronic bottles may unknowingly change 
the patients’ behavior in regards to medication 
adherence, and thus, the estimation of adherence 
provided might prove unreliable. They may also 
give the impression of continuous supervision of 
the patient and as a result, influence acceptance of 
the measurement method and the patients’ overall 
comfort [12].
Incorrect use of adherence-related terms may 
lead to some confusion and misunderstandings. The 
differences between adherence and persistence 
should be clearly explained to the patient and the 
distinctions emphasized. Patients who are included 
in the persistent cohort, can also be classified as 
showing poor adherence, while in the exact same 
clinical situation. Adherence is a fully qualitative 
concept, regarding quality use of the medication 
(Fig. 1). In contrast, persistence should be under-
stood in the quantitative scope [13, 14] and might 
be simply described as the duration of time from 
initiation to discontinuation of pharmacotherapy 
(Fig. 1). The concept of adherence is also frequently 
mistaken with compliance. Both terms might be 
described as the extent to which patients are consis-
tent with the health practitioner recommendations. 
At this point, we should just admit, that ‘patients’ 
compliance’ — frequently employed to describe 
medication-taking behavior, has a pejorative con-
notation and, thus, should not be widely used in the 
scientific deliberation (Fig. 1) [15].
The model of concordance serves a philosophi-
cal role, taking into account the shared understand-
ing between patients, physicians, pharmacists, 
and other healthcare providers. This agreement 
must be supported by mutual trust and confidence, 
where the physician and patient serve together as 
a team, bringing together highly advanced medi-
cal knowledge and the patient’s care for his or her 
own health [16].
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Adherence after AMI: General assessment
Non-diagnosed chronic coronary artery dis-
ease (CAD) can sometimes initially present as 
AMI. Due to the wide availability of high-quality 
medical care, in most cases, the patients’ primary 
condition is already diagnosed and well known. 
The majority of patients who have suffered an AMI 
have a long medical history of cardiovascular dis-
eases. This prevalence contributes to maintaining 
researchers’ interest in adherence-related issues in 
relation to AMI [17]. Patients with high adherence 
who used statins or beta-blockers were found to 
have a lower mortality risk when compared to those 
diagnosed with adherence-related problems [18]. 
Interestingly enough, long-term observations have 
indicated that the level of adherence decreases 
over time, with a 3-year medication continuation 
rate of 44% for statins, 48% for beta-blockers and 
43% for angiotensin-converting enzyme inhibitors 
(ACEI)/angiotensin II receptor blockers (ARB) 
[19]. In France, a 30-month follow-up in patients 
after AMI estimated the non-adherence rate to be 
24% for statins and 32% for beta-blockers [20]. 
Discontinuation of ACEI therapy was discovered 
at unacceptable rates — 7% at 1 month following 
AMI, 22% at 6 months and approximately 50% at 
1 year. It is possible that financial difficulties were 
a key factor that could help predict the possibility of 
discontinuation of the recommended therapy [21]. 
Every effort to improve adherence should be 
undertaken in order to optimize pharmacotherapy 
and achieve better patient outcomes. Neverthe-
less, as adherence-related problems are multidi-
mensional, 100%-adherence is extremely difficult 
to achieve, if not impossible. We believe that each 
case should be assessed individually — allowing 
us to predict the problems that may occur with our 
prescribed therapies, anticipate them, and teach 
our patients how to prevent them. The develop-
ment of effective interventions has proven to be 
a tremendous challenge in all areas of medicine [22].
Non-adherence predicting factors:  
A multidimensional approach
Adherence is a multidimensional issue, which 
is why many studies have focused on trying to pin-
point the factors that may constitute a significant 
contribution to patients’ behavior in relation to 
medication management, especially in the context 
of AMI (Fig. 2). In one single center observa-
tion, both ST-elevation myocardial infarction (vs. 
non-ST-elevation myocardial infarction) and male 
gender were suggested to predict non-adherence, 
while 3-vessel CAD was associated with a higher 
level of adherence when patients were treated with 
clopidogrel [23]. Comorbidities such as diabetes, 
hypertension, or atrial fibrillation may indicate 
problems not only with compliance regarding the 
physician’s recommendations, but also with turn-
ing in the prescription for receipt of antiplatelet 
drugs [24, 25]. Elderly patients, smokers, patients 
with silent ischemia or no previous AMI, or those 
patients with no coronary artery bypass graft, 
mainly discontinued DAPT due to non-adherence 
or bleeding [26]. The patient’s state of mental 
health — e.g. depression [27] or an unmarried sta-
tus [28] seems to be associated with a higher risk 
of non-adherence as well. Research has proven, to 
put it simply, that adherence-related issues depend 
on the patients’ behavior. Patients who have been 
classified with poor adherence before the initiation 
of antiplatelet therapy, after AMI may be even 
Figure 1. Definitions of adherence, persistence, and compliance.
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more likely to discontinue treatment, without any 
logical reason [29]. As mentioned before, financial 
limitations may affect adherence as well. Indeed, 
a lower education level, immigrant status, and poor 
transitions in care were all documented as common 
barriers to clopidogrel adherence [30]. Pallares et 
al. [31] concluded that financial obstacles in the 
non-adherent vs. adherent group were identified 
as 42% vs. 36%. Surprisingly, adherent patients 
reported a higher co-payment rate [31]. In a dif-
ferent study, 62% of respondents listed the cost of 
a medication as a potential reason for their choice 
to discontinue therapy [28]. Patients already on 
DAPT, those with previous or in-hospital bleeding, 
or patients using oral anticoagulation were all 
determined to have a higher probability of non-
-adherence, subsequently increasing their risk 
of stent thrombosis [32]. There is no doubt, that 
avoiding the side effects of certain medications 
plays a critical role in a patient’s adherence to 
treatment, especially those with AMI. According 
to legislation in the European Union, the report-
ing of adverse drug reactions to the appropriate 
regulatory authorities is obligatory for physicians, 
pharmacists and nurses. Other factors proven to 
play a role in adherence-related issues include poor 
communication between patients and their physi-
cians, and the patients’ lack of knowledge regarding 
their own medication regimens [33]. Investigating 
non-adherence within a group of ACS referred for 
urgent PCI, we must take into account the substan-
tial heterogeneity in baseline characteristics, data 
sources, and various P2Y12-inhibitor resistance. 
It is essential to remember the diversity present 
across a variety of regional medical practices that 
may play a critical role in the level of adherence 
amongst patients who were treated differently for 
ACS. As the side effects and safety profiles of se-
veral P2Y12 inhibitors differ, it is hard to address 
whether rates of adherence vary according to the 
type of DAPT prescribed [26]. Simplified drug 
regime, which is directly associated with the impro-
vement of adherence level, led consequently to the 
introduction of fixed dose combination and polypill 
concept. Indeed, in patients after AMI, covering 
a broad range of different socioeconomic strata, 
the use of polypill strategy increased self-reported 
and directly-measured medication adherence for 
secondary prevention [34]. Since number of stud-
ies, including RCTs, demonstrated the convenient 
reduction of multiple risk factors after the reduc-
tion of dosage demands, the concept of polypill 
has been implemented into European Society of 
Cardiology guidelines [35–37].
Adherence after AMI treated by PCI
Although new-generation drug-eluting stents 
(DES) have been designed to decrease device 
related outcomes, early discontinuation of DAPT 
is still the most powerful predictor of stent throm-
bosis. Unfortunately, many patients with ACS fre-
quently discontinue DAPT due to non-adherence 
or bleeding [26]. DAPT adherence, although high at 
1 month, decreases substantially by 6 months [26]. 
Much of the literature describes the direct relation-
ship of failure to adhere to therapy with poorer 
patient outcomes [32]. Patients who disrupted 
their DAPT due to non-adherence or bleeding 
are at the highest risk of a poorer outcome; those 
discontinuing DAPT temporarily due to a need for 
surgery, or permanently due to the completion of 
therapy, are at a lower risk [32]. Recently published 
studies have confirmed that adherence in patients 
after myocardial intervention with PCI could be 
considered unexpectedly high. In the German 
population, the adherence level was estimated at 
90.8% for ASA and at 79.2% for ACEI or ARB. Al-
though the above-mentioned study had a relatively 
Figure 2. Adherence after acute myocardial infraction (AMI) — summary; STEMI — ST-segment elevation myocardial 
infarction; NSTEMI — non-ST-segment elevation myocardial infarction. 
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large patient cohort, the study was conducted in 
a single medical center; which could raise some 
important issues regarding the generalization of 
results and conclusions [38]. Even a delay in filling 
the first prescription after invasive coronary treat-
ment could be associated with unexpected, adverse 
clinical outcomes. Based on data obtained from 
a British-Columbian consortium, the postponement 
of handing in a prescription, for more than 3 days 
projected with possible mortality and/or recur-
rent AMI [39]. These results are consistent with 
other studies that analyzed patients who received 
their prescription for clopidogrel successfully on 
the day of hospital discharge after DES implanta-
tion against patients who delayed the purchase of 
clopidogrel. The latter group was found to have 
a higher probability of sudden death or recurrent 
myocardial infarction (14.2% vs. 7.9%; p < 0.001) 
[40]. One study demonstrated that as many as 1 in 
7 patients treated with DES discontinued thieno-
pyridines therapy (clopidogrel, prasugrel or ticlopi-
dine) without any reasonable medical reason within 
the first month following their procedure [41]. 
French researchers have estimated the risk of dis-
continuation of therapy after 1 month, in relation to 
ASA and after 3 months of clopidogrel treatment, at 
18.6%, with an increase to 49.1% after 12 months. 
It is possible that the adherence-related issues 
might be a reflection of the well-described phe-
nomena of many patients’ resistance to antiplatelet 
treatment [42]. These results are consistent with 
the observations of an Italian study where only 54% 
of patients during a 6-month follow-up visit were 
determined to be receiving appropriate antiplatelet 
therapy [43]. Zhu et al. [24] estimated the level 
of adherence for clopidogrel at 66.8%, based on 
a patient cohort of 10,465 people, aged 18–65 years. 
Although adherence is mainly assessed in 
relation to clopidogrel, one study has investigated 
patient adherence to prasugrel, estimating the 
patient’s use of prasugrel with the medication 
possession ratio (MPR). MPR has proven a suit-
able tool for the measurement of adherence level 
in regards to large sample sizes, particularly when 
data is obtained from pharmacy refill statistics. In 
the study concerning prasugrel, 69% of patients 
were classified within the good adherence group, 
with an MPR ≥ 80% [27]. 
After reviewing the data provided from the 
8-item Morisky Medication Adherence Scale 
(MMAS-8), Muntner et al. [29] observed low ad-
herence in 11% of patients discharged home after 
PCI. Harjai et al. [44] in a prospective observation, 
demonstrated that the continuation of DAPT bey-
ond 12 months in patients undergoing PCI of native 
coronaries, who survived with no major adverse 
cardiac events (MACE), did not confer long-term 
protection from death or myocardial infarction. 
Ferreira-Gonzales et al. [45] has suggested that 
the discontinuation of DAPT after DES implanta-
tion within 1 year following the invasive procedure 
is not significantly associated with the risk of an 
occurrence of MACE during the follow-up. In fact, 
discontinuation, was often of a temporary nature 
(on average 7 days) and associated with clopidogrel 
treatment. The level of adherence was estimated 
based on patients’ declarations only, which was 
a major limitation of the study. A different study 
reported the increase of MACE due to discontinua-
tion of clopidogrel within the initial 3-month period, 
but not after 3 to 12 months [46]. 
Implications on routine practice
Both physicians in clinical practice and phar-
macists should be constantly assessing patient 
adherence to treatment regimens [47]. Adherence-
related issues are an extremely important subject 
matter to be discussed during the initial medical 
examination. In our opinion, a patient’s adher-
ence level may drastically change throughout the 
therapeutic process. During the initial phase of 
diagnosis and treatment, patients’ knowledge about 
their disease and belief in recovery is much higher 
than when compared to beliefs after a long period 
of extensive therapy. This is why physicians should 
never underestimate adherence-related issues. 
Pharmacists can provided adherence-related 
interventions, based on simple tools such as 
questionnaires aiming at identifying non-adherent 
patients [48]. As previously mentioned, one 
of the latest systematic reviews indicated that 
a lack of patient education in regards to antiplatelet 
therapy may have an impact on adherence levels 
[49]. Indeed, interventions aimed at improving and 
expanding health education should be established 
as one of the most promising methods in order to 
prevent non-adherence. Each healthcare profes-
sional has an moral obligation to their patients 
to not only treat them, but also to educate their 
patients about their illness and therapies, and 
thus, should be willing to join in the campaign 
against non-adherence. Community pharmacies 
could play an additional role in patient education, 
as they are easily accessible to patients, have 
front-line access to refill statistics, and are the 
medical professional the patient sees most often. 
Through their dedication to patient adherence 
activities, pharmacists could help lead to better 
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adherence rates among patients in ACS settings 
undergoing stent implantation. Therefore, the role 
of a pharmacist should change, from that solely of 
a medication dispenser, to one that is much more 
patient-oriented. In countries such as the United 
Kingdom or Canada — often considered the global 
capital of advanced pharmaceutical services, these 
processes are well implemented and have been 
further introduced into both practical and routine 
clinical settings [50]. 
It is crucial that we focus on the improve-
ment of communications with patients — not 
only in quantity but also, and especially, in quality. 
Patients desire that physicians and pharmacists 
speak with them using simple terminology, avoid-
ing unnecessary medical jargon. This focus on 
quality communications should be undertaken by 
the healthcare system as a whole, as it plays an 
important role in patient adherence. After hospi-
talization, patients should be able to quickly and 
efficiently familiarize themselves with all the nec-
essary recommendations for further treatment and 
care, not only concerning pharmacological therapy 
but also in regards to lifestyle changes, nutrition 
and addictions. The role of healthcare profession-
als is to promote adherence-related knowledge 
in an acceptable, non-intrusive way, allowing the 
patient to gain control over their own health. It is 
completely unacceptable for members of healthcare 
teams to undermine the professional authority of 
other healthcare practitioners in the presence of 
a patient. Mutual respect among physicians, nurses, 
pharmacists and other members of the healthcare 
system may have a large impact on patient behavior 
and consequently on their adherence to treatment.
Optimal adherence: A challenge  
for the near future
Although patient adherence at times seems 
an uncertain guessing game, the development of 
evidence-based interventions are strongly recom-
mended, particularly actions that help promote 
adherence [51]. The necessity to conduct RCTs has 
been frequently pointed out in relevant literature, 
especially in the context of distinguishing interven-
tions aimed at primary and secondary prevention 
of cardiovascular diseases [52]. Patients suffering 
from cardiovascular diseases, who received assis-
tance from their pharmacist, exhibited a decrease 
in the systolic and diastolic blood pressure, total 
cholesterol or — in the context of public health is-
sues — showed a decrease in smoking habits [53]. 
Of note, one single-center observation showed that 
telephone contact with patients who were implan-
ted with DES resulted in “near-perfect” DAPT 
adherence. Phone calls were made by nurses 7 days 
after the procedure, and then 1, 6, and 9 months 
following hospital discharge. The protocol of the 
trial was based on randomized selection. Whether 
these results could be implemented broadly, par-
ticularly in patients with ACS, is worthy of further 
investigation [54]. 
From the methodological point of view, re-
search should focus on pinpointing the connections 
between the different ways of measuring adher-
ence. As most antiplatelet drugs are reimbursed, 
the comparison of data obtained from pharmacy 
refills and from self-reported questionnaires, is 
not so complicated. To fully understand adherence-
related issues, research should not only focus 
on adherence to antiplatelet therapy but other 
therapies as well. The limited number of works 
estimating adherence related to different types of 
medication other than antiplatelet agents could lead 
to an underestimation of the problem. 
Moreover, in our opinion, the clinical ‘resis-
tance’ to antiplatelet treatment that is described in 
the literature may be in fact, associated with poor 
adherence [55, 56]. Research could help distinguish 
the reasons for this phenomena — those which 
are due to poor adherence, in contrast with those 
which might be associated with an unexplored 
pharmacological background. 
Last but not least, the strong need for large-co-
hort and multi-center studies in regards to patient 
adherence should be emphasized. As such, follow-
up monitoring should be extended to a longer time 
period — 5 years or more, which we believe crucial 
from an epidemiological point of view.
To summarize, the first and most essential 
change to improve adherence, is to expand the 
communication between patients and physicians, 
both in quality and quantity. This is an extremely 
important target for interventions aimed at increas-
ing DAPT adherence. Implementing a larger role 
of clinical pharmacists on the cardiology wards, 
and in follow-up care, could potentially improve 
adherence in patients undergoing PCI after ACS. 
Interprofessional collaboration is strongly needed 
to help realize and execute direct patient educa-
tion. Indeed, interventions aimed at improving and 
expanding health education should be established 
as one of the most promising methods in order to 
prevent non-adherence.
Adherence-related issues require more pro-
found and advanced research, especially in the 
context of AMI treated with PCI. Currently, the 
majority of studies are conducted with regards to 
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antiplatelet therapy [57]. Assessment of adherence 
to different types of medication or those estimating 
the adherence to non-pharmacological treatment 
e.g. lifestyle recommendations, in large-cohorts is 
nowadays strongly desired. The development of 
effective interventions to improve adherence has 
proven to be a tremendous challenge in all areas of 
medicine; and as such, requires a multi-disciplinary 
focus, as adherence is an issue that concerns both 
healthcare practitioners and scientists.
This paper contributes to the global discus-
sion on the incremental implications of research 
in adherence-related issues.
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